Alleviating Effects Against High Intraocular Pressure by Oral Intake of Cordyceps Cicadae Mycelia

NCT05304299 | Completed DMC

• 1 other identifier: IRB-19-024
• Study Type: interventional
• Target: 46
• Locations: 1 country
• Sites: 1

Brief Summary

This study will investigate the effects of lowering intraocular pressure by oral intake of Cordyceps cicadae mycelia, to provide evidence-based data for high intraocular pressure relief.

Conditions

Supplement

Outcome Measures

Primary Outcomes (4)

• Intraocular pressure

  Intraocular pressure of both eyes will be assessed

  0 minutes (before given Cordyceps Cicadae Mycelia)

• Intraocular pressure

  Intraocular pressure of both eyes will be assessed

  90 minutes after given Cordyceps Cicadae Mycelia

• Blood pressure

  Both systolic and diastolic blood pressures will be assessed

  0 minutes (before given Cordyceps Cicadae Mycelia)

• Blood pressure

  Both systolic and diastolic blood pressures will be assessed

  90 minutes after given Cordyceps Cicadae Mycelia

Study Arms (2)

Cordyceps Cicadae Mycelia only

EXPERIMENTAL

Only Cordyceps Cicadae Mycelia will be given.

Dietary Supplement: Cordyceps Cicadae Mycelia

Cordyceps Cicadae Mycelia with Taflotan (saflutan)

EXPERIMENTAL

Cordyceps Cicadae Mycelia with Taflotan (saflutan) will be given.

Dietary Supplement: Cordyceps Cicadae Mycelia

Interventions

Cordyceps Cicadae Mycelia DIETARY_SUPPLEMENT

Cordyceps Cicadae Mycelia will be given to test its potential for alleviation of high intraocular pressure.

Cordyceps Cicadae Mycelia only; Cordyceps Cicadae Mycelia with Taflotan (saflutan)

Eligibility Criteria

• Age: 20 Years - 75 Years
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)

You may qualify if:

• Age between 20 and 75 years old, regardless of gender.
• Pre-test confirmation of high intraocular pressure.
• Subjects should understand the trial and agree to join the project.

You may not qualify if:

• Age under 20 or over 75 years.
• Use intraocular pressure lowering drugs other than Taflotan (saflutan).
• Using beta-blockers or diuretics.
• Being pregnant.
• Disabled individuals with specific diseases or malfunction, for example tumours at terminal stage, blindness.
• Loss of self-consciousness and behavioral capacity.
• Patients with major diseases.
• Withdrawal criteria All subjects may withdraw at any time without any reason. The act of withdraw does not affect rights for them to seek medical advice or treatments.

Sponsors & Collaborators

• Han-Hsin Chang: lead
• Grape King Bio Ltd.: collaborator

Study Sites (1)

Han-Hsin Chang

Taichung, Taiwan

Location

Study Officials

• Han-Hsin Chang, PhD

  Chung Shan Medical University

  PRINCIPAL INVESTIGATOR

Study Design

• Study Type: interventional
• Phase: not applicable
• Allocation: NON RANDOMIZED
• Masking: NONE
• Purpose: PREVENTION
• Intervention Model: PARALLEL
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Principal Investigator

Model Details: Two groups of subjects are subject to pre-test and post-test intraocular pressure measurements.

Study Record Dates

• First Submitted: March 4, 2022
• First Posted: March 31, 2022
• Study Start: March 10, 2020
• Primary Completion: July 31, 2021
• Study Completion: December 31, 2021
• Last Updated: March 31, 2022

Record last verified: 2022-03

Data Sharing

• IPD Sharing: Will not share

Locations

TW (1)